Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI356 in Adults With Moderate-to-Severe Atopic Dermatitis
CTR20254959Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI356 in atopic dermatitis (AD), sponsored by InnoCare Pharma. Started Dec 2025; status: active.
02
Drugs
IBI356
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20254959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254959.